Method and system for use in treating a patient with immunosuppresants using whole blood level criteria to prevent an adverse immune response
Patent 5694950 Issued on December 9, 1997. Estimated Expiration Date: 
December 9, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
December 9, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesComputer system and method for suggesting treatments for physical trauma Method for determining therapeutic drug dosage using bioelectrical resistance and reactance measurements Diabetes management system and apparatus Method for use in treating a patient with FK 506 to prevent an adverse immune response Patent #: 5365948 InventorAssigneeApplicationNo. 291223 filed on 08/16/1994US Classes:128/898, Methods540/455Polycyclo ring system which contains the hetero ring as one of the cyclosExaminersPrimary: Lacyk, John P.Attorney, Agent or FirmInternational ClassA61B 017/00AbstractA method and system for use in treating a patient with an immunosuppressant to prevent an adverse immune response, either a rejection of a transplanted organ or an attack on the patient's body by its own immune system caused by an autoimmune disease, without unduly suppressing the ability of the patient's immune system to combat infection. The method employs an expert system to provide non-numerical information concerning the course of action to be taken with respect to a patient's immunosuppressant treatment, at a given time, including, in particular, an instruction on whether the immunosuppressant dosage being administered to the patient should be changed, and if so how. That instruction is determined by the expert system through analysis of standardized characterizations assigned to standardized patient examination criteria including levels of the immunosuppressant in blood plasma and whole blood. The method also employs a means for determining the actual numerical immunosuppressant dosage the patient should receive at a given time.Other References
|
| ||||||||||||||
